Increased Pricing Pressure From Generic Competition Will See Major Players Facing Disappointing Performances In The CNS Market
Understand the most attractive market sectors and discover what will influence competitive strategy and franchise development

/Pharmaceutical News Articles/ -- Research and Markets (http://www.researchandmarkets.com/reports/c7834) has announced the addition of The CNS Market Outlook to 2009 to their offering

Forecast the future growth of the major CNS markets and assess the strategies leading players are implementing to boost their product success with this latest report.

The new management report 'The CNS Market Outlook to 2009' provides in-depth analysis of the current growth opportunities, threats, leading players and their future prospects. It will enable you to understand the most attractive market sectors and discover what will influence competitive strategy and franchise development.

As traditional markets stagnate, many major pharmaceutical companies have been slow to seize opportunities to develop markets and key growth indications. At the same time, increased pricing pressure from generic competition and limited differentiation among new medicines will see some major players facing disappointing performances and prompting strategic changes.

Identify the potential growth areas within key CNS markets (Alzheimer’s disease, depression, epilepsy, migraine, multiple sclerosis, pain, Parkinson’s disease and schizophrenia) and formulate the most effective future strategy for your company to reduce resource wastage.

'In 2003, sales of J&J's CNS portfolio are estimated to have grown at 21.9%, compared to 19.7% in 2002. Barring the performance of Ultram, the picture is overwhelmingly one of sustained growth, driven by the strong performances of Duragesic, Risperdal and Topamax…'

Key findings of the report

- Key patent expiries in the schizophrenia market, and weak performances from several new launches are set to propel BMS, through its new product Abilify, to become an increasingly dominant force in the schizophrenia market.

- The depression market is forecast to offer declining returns. However, the late-stage pipelines of the major pharmaceutical companies will continue to be dominated by medicines for this indication.

- GSK, the second largest player in the CNS sector in 2003, is forecast to suffer further weak performance over the next five years, before its strong early stage pipeline comes to market.

- Driven by aggressive in-licensing, Pfizer is forecast to consolidate its position of industry leader towards 2009, despite a disappointing performance from some new launches.

- In terms of sales growth, the major drivers in the CNS sector are the AD, MD and Schizophrenia markets. Future growth will be driven by a small number of blockbuster products.


“According to opinion leaders, the main clinical unmet needs in MS include the induction and maintenance of remission, altering disease progression and improvement in cognitive function. The reduction in the frequency of MS relapses may contribute significantly to increasing the quality of life of MS sufferers...�

The answers to your questions

- What will be the major growth indications in the CNS area between 2004 and 2009?
- What are the key drivers of growth and how will new launches affect the CNS market?
- How have recent major launches from Pfizer, Novartis, Lilly and BMS performed?
- Which companies will become the key players in the CNS area?
- Which products will be impacted by generic competitors?
- Which pipeline products will be the growth drivers of the future?
- Which indications are forecast to have the highest levels of market potential?

"Whilst MDD (major depressive disorder) is the dominant depressive disorder that can be treated through pharmacological therapy, co-morbidities are very frequently diagnosed. Co-morbidities associated with MDD represent an important target for marketers, facilitating prescription growth and lifecycle extensions for existing MDD treatments..."

Why you should order your copy today

- Discover which indications have the greatest potential to provide franchise growth and how the pharmaceutical industry is attempting to exploit these opportunities.
- Compare the franchises of top pharmaceutical marketers across major indications, and evaluate how market share of leading companies, such as GSK, Johnson and Johnson and Eli Lilly will change over the next 6 years.
- Analyze how recent events are affecting the performance of major products and how marketers are confronting competitive changes in CNS marketplace.
- Gain up-to-date competitive intelligence across the CNS sector and understand the major issues affecting key pharmaceutical marketers.
- Use head-to head comparisons of the CNS pipelines of the top ten leading players to identify which companies will have a presence among key indications over the next 6 years.

"Despite being competitive, the nociceptive pain market is arguably the most attractive in terms of the factors described in the above table. The market boasts by far the greatest patient population, and is predicted to be worth considerably more than the other markets in 2009..."

Executive Summary 12

Chapter 1 Patient Potential 12
Chapter 2 Global Market Analysis 13
Chapter 3 Global Players in the CNS Market 14
Chapter 4 Development of Key Market Segments to 2009 15


For more information visit http://www.researchandmarkets.com/reports/c7834

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

Press Release Contact Information:

Patrick Good
Research and Markets
Press Officer
Voice: 00353 1 4151243
Fax: 00353 1 4100980